Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis.

ABSTRACT:

Background

Efficacy trials showed that glucagon-like peptide-1 receptor (GLP1R) agonists reduced metabolic risk factors in addition to glucose lowering, but the cardiovascular and microvascular efficacy of this drug class remains to be determined. We aimed to evaluate the overall cardiovascular and microvascular efficacy of GLP1R agonists by performing a meta-analysis with trial sequential analysis.

Methods

Randomized controlled, cardiovascular outcomes trials including at least 2000 patient-years' follow-up and 100 composite cardiovascular events were included. Trial sequential analysis (TSA) was performed and the quality of evidence was graded.

Results

Thirty-three thousand four hundred fifty-seven patients and 4105 cardiovascular events from 4 large trials were inc

SUBMITTER: Zhang X 

PROVIDER: S-EPMC6142638 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature